mhurhangee/ep-ind-claims huggingface dataset:
A micro-needle device comprising: a substrate; a micro-needle provided on the substrate; and a physiologically active composition deposited on the micro-needle and/or the substrate, wherein the physiologically active composition contains: at least one polyhydric alcohol selected from glycerin, ethylene glycol, propylene glycol and 1,3-butylene glycol; at least one compound selected from polyethylene glycol, chondroitin sulfate, dextran, croscarmellose sodium and a metal chloride; and a physiologically active substance, and contains substantially no water. a substrate; a micro-needle provided on the substrate; and a physiologically active composition deposited on the micro-needle and/or the substrate, wherein the physiologically active composition contains: at least one polyhydric alcohol selected from glycerin, ethylene glycol, propylene glycol and 1,3-butylene glycol; at least one compound selected from polyethylene glycol, chondroitin sulfate, dextran, croscarmellose sodium and a metal chloride; and a physiologically active substance, at least one polyhydric alcohol selected from glycerin, ethylene glycol, propylene glycol and 1,3-butylene glycol; at least one compound selected from polyethylene glycol, chondroitin sulfate, dextran, croscarmellose sodium and a metal chloride; and a physiologically active substance, and contains substantially no water.
Device for the supply of a gas comprising: • a plurality of gas vessels, preferably in the form of gas cylinders; • a frame comprising a lower portion, an upper portion, and a plurality of side portions, defining a space for arranging said plurality of gas vessels; • a hooking element coupled to said upper portion of said frame, configured to cooperate with a hook or similar element of an external machine adapted to lift said device, said hooking element being coupled to said frame in a movable manner, at least between an operative position and a rest position; characterized in that the device comprises an activation mechanism (9a, 9b, 9c) mechanically coupled to the hooking element, comprising a control portion, that is operable by a user to move said hooking element between said operative position and said rest position; and in that said activation mechanism comprises a first bar coupled to said hooking element and a second bar coupled to said first bar, said first bar arranged at said upper portion of said frame, said second bar arranged at one of said side portions of said frame, said second bar comprising, or being coupled to, said control portion, preferably the second bar being indirectly linked to the first bar, via one or more further elements, so that movement of the second bar causes movement of the first bar. • a plurality of gas vessels, preferably in the form of gas cylinders; • a frame comprising a lower portion, an upper portion, and a plurality of side portions, defining a space for arranging said plurality of gas vessels; • a hooking element coupled to said upper portion of said frame, configured to cooperate with a hook or similar element of an external machine adapted to lift said device, said hooking element being coupled to said frame in a movable manner, at least between an operative position and a rest position; characterized in that the device comprises an activation mechanism (9a, 9b, 9c) mechanically coupled to the hooking element, comprising a control portion, that is operable by a user to move said hooking element between said operative position and said rest position; and in that said activation mechanism comprises a first bar coupled to said hooking element and a second bar coupled to said first bar, said first bar arranged at said upper portion of said frame, said second bar arranged at one of said side portions of said frame, said second bar comprising, or being coupled to, said control portion, preferably the second bar being indirectly linked to the first bar, via one or more further elements, so that movement of the second bar causes movement of the first bar.
Multi-component composition comprising A) a polyol component comprising one or more polyols and water, B) a polyisocyanate component comprising hexamethylene diisocyanate and an isocyanate-functional polyurethane prepolymer of at least one polyol and methylene diphenyl diisocyanate, or HDI and MDI, wherein the HDI used is selected from monomeric HDI, HDI biurets, HDI isocyanurates, HDI trimer, allophanate derivatives of HDI, uretdione dimer of HDI or mixtures thereof, and C) a powder component comprising one or more hydraulic binding agents and one or more aggregates. A) a polyol component comprising one or more polyols and water, B) a polyisocyanate component comprising hexamethylene diisocyanate and an isocyanate-functional polyurethane prepolymer of at least one polyol and methylene diphenyl diisocyanate, or HDI and MDI, wherein the HDI used is selected from monomeric HDI, HDI biurets, HDI isocyanurates, HDI trimer, allophanate derivatives of HDI, uretdione dimer of HDI or mixtures thereof, and HDI and MDI, wherein the HDI used is selected from monomeric HDI, HDI biurets, HDI isocyanurates, HDI trimer, allophanate derivatives of HDI, uretdione dimer of HDI or mixtures thereof, and C) a powder component comprising one or more hydraulic binding agents and one or more aggregates.
A device for monitoring a patient to evaluate a heart failure condition of a patient comprising: a patient interface; a sensor configured to generate a signal associated with a characteristic of patient respiration; and a sensor configured to generate a signal representative of a respiratory treatment pressure, and a processor, coupled with the sensor configured to generate the signal associated with a characteristic of patient respiration, the processor being configured to control a determination of a heart failure condition change indicator based on a measure of the respiratory treatment pressure and a respiratory parameter determined from the characteristic of respiration, the indicator representing information about a change in a heart failure condition of the patient; wherein the processor is configured to perform a threshold comparison of the respiratory parameter determined by the processor, and wherein a result of the comparison triggers a heart failure condition message. a patient interface; a sensor configured to generate a signal associated with a characteristic of patient respiration; and a sensor configured to generate a signal representative of a respiratory treatment pressure, and a processor, coupled with the sensor configured to generate the signal associated with a characteristic of patient respiration, the processor being configured to control a determination of a heart failure condition change indicator based on a measure of the respiratory treatment pressure and a respiratory parameter determined from the characteristic of respiration, the indicator representing information about a change in a heart failure condition of the patient; wherein the processor is configured to perform a threshold comparison of the respiratory parameter determined by the processor, and wherein a result of the comparison triggers a heart failure condition message.
Process for the preparation of an α-nucleated polypropylene composition, comprising the steps of a) forming a polypropylene composition comprising a polymeric nucleating agent, said polypropylene composition having a melt flow rate MFR 2 measured in accordance with ISO 1133 (230 °C, 2.16 kg) in the range of 0.1 to 500 g/10 min, a pentad regularity determined by 13 C-NMR spectroscopy of at least 95.0 mol-%, a solidification temperature Ts 400 of at least 50 °C and a heat of crystallization (Hc) at a cooling rate of 200 K/s of at least 30 J/g, b) heating the polypropylene composition obtained in step a) to a melt temperature of at least 200 °C c) exposing the melt obtained in step b) to a cooling rate of 200 K/sec or more. a) forming a polypropylene composition comprising a polymeric nucleating agent, said polypropylene composition having a melt flow rate MFR 2 measured in accordance with ISO 1133 (230 °C, 2.16 kg) in the range of 0.1 to 500 g/10 min, a pentad regularity determined by 13 C-NMR spectroscopy of at least 95.0 mol-%, a solidification temperature Ts 400 of at least 50 °C and a heat of crystallization (Hc) at a cooling rate of 200 K/s of at least 30 J/g, b) heating the polypropylene composition obtained in step a) to a melt temperature of at least 200 °C c) exposing the melt obtained in step b) to a cooling rate of 200 K/sec or more.
An N -substituted azetidine derivative selected from the group consisting of compounds according to any one of Formulae 1 or a pharmaceutically acceptable salt thereof. wherein R1 is (C1-8)alkyl, (C3-8)cycloalkyl, (C3-6)heterocycloalkyl, (C2-6)alkenyl, (C2-6)alkynyl, (C1-4)alkylcarbonyl, (C1-4)alkoxy(C2-4)alkyl, (C3-6)cycloalkyl(C1-3)alkyl, (C3-6)hetero-cycloalkyl(C1-3)alkyl, each independently optionally substituted with one or more halogen, nitrile, hydroxyl or (Cl-2)alkyl; (h)Ar is a (hetero) aromatic ring, optionally substituted with R12 and R13; R2 and R3 are independently of each other H, fluorine, chlorine, (C1-3)alkyl, (C1-3)alkoxy, (C1-3)alkylthio, CF 3 or nitrile; R4 and R7 are independently of each other H, fluorine, chlorine, (C1-2)alkyl, CF 3 or nitrile; R12 is H, fluorine, chlorine, (C1-2)alkyl, (C1-2)alkoxy, nitrile or hydroxyl; R13 is H, fluorine, chlorine, (C1-3)alkyl, (C1-3)alkoxy, (C1-3)alkylthio, CF 3 or nitrile; R6 is H, hydroxyl, amine or (C1-6)alkoxy; R6 and R2 may be linked to form a (hetero)aromatic ring which is optionally substituted with fluorine, chlorine or (C1-3)alkyl. R1 is (C1-8)alkyl, (C3-8)cycloalkyl, (C3-6)heterocycloalkyl, (C2-6)alkenyl, (C2-6)alkynyl, (C1-4)alkylcarbonyl, (C1-4)alkoxy(C2-4)alkyl, (C3-6)cycloalkyl(C1-3)alkyl, (C3-6)hetero-cycloalkyl(C1-3)alkyl, each independently optionally substituted with one or more halogen, nitrile, hydroxyl or (Cl-2)alkyl; (h)Ar is a (hetero) aromatic ring, optionally substituted with R12 and R13; R2 and R3 are independently of each other H, fluorine, chlorine, (C1-3)alkyl, (C1-3)alkoxy, (C1-3)alkylthio, CF 3 or nitrile; R4 and R7 are independently of each other H, fluorine, chlorine, (C1-2)alkyl, CF 3 or nitrile; R12 is H, fluorine, chlorine, (C1-2)alkyl, (C1-2)alkoxy, nitrile or hydroxyl; R13 is H, fluorine, chlorine, (C1-3)alkyl, (C1-3)alkoxy, (C1-3)alkylthio, CF 3 or nitrile; R6 is H, hydroxyl, amine or (C1-6)alkoxy; R6 and R2 may be linked to form a (hetero)aromatic ring which is optionally substituted with fluorine, chlorine or (C1-3)alkyl.
A process for producing a resist solvent for producing electronic parts or a rinsing liquid for producing electronic parts consisting of an organic acid ester-type liquid containing an organic peroxide at a peroxide-value of 0.5 mmoL/kg or less, measured in accordance with ISO 3960:2007 fourth edition, 9968, said process comprising contacting an organic peroxide-containing organic acid ester-type liquid with a platinum group metal catalyst carried on a synthetic resin to remove said organic peroxide from said organic acid ester-type liquid.
A composition comprising a physiologically acceptable carrier and a compound of Formula: Formula, wherein m = 1, 2, or 3; R 4 and R5 are independently selected from C 1 -C 4 alkyl, C 1 -C 4 heteroalkyl, allyl, heteroallyl, aryl, hydroxyl and when bound together, can form part of an aliphatic or heterocyclic ring system; R 6 is selected from allyl, alkenyl, aryl alkyl, C 4 -C 6 alkyl, halo alkyl, halo alkenyl or propargyl; X - is a pharmaceutically acceptable anion, and including any salts or solvates thereof, wherein the compound is selected from the group consisting of: [ -but-2-enyl]-(2-hydroxyethyl)-methyl-sulfonium bromide, Propargyl-(2-hydroxyethyl)-methylsulfonium bromide, Allyl-(2-hydroxyethyl)-methyl-sulfonium bromide, lodomethyl-(2-hydroxyethyl) -methyl- sulfonium chloride, and including any acceptable salts or solvates thereof. wherein m = 1, 2, or 3; R 4 and R5 are independently selected from C 1 -C 4 alkyl, C 1 -C 4 heteroalkyl, allyl, heteroallyl, aryl, hydroxyl and when bound together, can form part of an aliphatic or heterocyclic ring system; R 6 is selected from allyl, alkenyl, aryl alkyl, C 4 -C 6 alkyl, halo alkyl, halo alkenyl or propargyl; X - is a pharmaceutically acceptable anion, and including any salts or solvates thereof, wherein the compound is selected from the group consisting of: [ -but-2-enyl]-(2-hydroxyethyl)-methyl-sulfonium bromide, Propargyl-(2-hydroxyethyl)-methylsulfonium bromide, Allyl-(2-hydroxyethyl)-methyl-sulfonium bromide, lodomethyl-(2-hydroxyethyl) -methyl- sulfonium chloride, and including any acceptable salts or solvates thereof.
A method for providing information on a status of a broadcasting network from a base station (40; 140) to a mobile station (10; 110) in a mobile communication system providing at least one broadcast/multicast service, BCMCS, the method comprising the steps of: recognizing, by the base station (40; 140), the status of the broadcasting network; and transmitting, by the base station (40; 140), a message including status information related to the status of the broadcasting network, the status information indicating a reason for the at least one BCMCS not being received by the mobile station (10; 110), wherein the status information represents one of a BCMCS parameter reset status, a BCMCS stop status, a BCMCS unavailable status, and a BCMCS protocol update status in the broadcasting network. recognizing, by the base station (40; 140), the status of the broadcasting network; and transmitting, by the base station (40; 140), a message including status information related to the status of the broadcasting network, the status information indicating a reason for the at least one BCMCS not being received by the mobile station (10; 110), wherein the status information represents one of a BCMCS parameter reset status, a BCMCS stop status, a BCMCS unavailable status, and a BCMCS protocol update status in the broadcasting network.
Feed-through, through a housing component of a housing, in particular of a battery housing, or battery cell housing, having an inner side (10.1) and an outer side (10.2), wherein the feed-through comprises: - a housing component which is made of a light metal and has at least one opening (5, 105, 1130.1, 1130.2), - at least one conductor, preferably a substantially pin-shaped conductor (7, 107, 1140.1, 1140.2), which is fed through the opening, - a glass or glass-ceramic material (20, 120, 2200) which at least partially surrounds the conductor, characterized in that the glass or glass-ceramic material is joined directly to the inner side (10.1) of the housing component by means of an ultrasonic welded join, without any contact material, wherein the inner side (10.1) is the side of the housing component that is directed into the interior of the battery when the housing component is configured as part of a battery housing. - a housing component which is made of a light metal and has at least one opening (5, 105, 1130.1, 1130.2), - at least one conductor, preferably a substantially pin-shaped conductor (7, 107, 1140.1, 1140.2), which is fed through the opening, - a glass or glass-ceramic material (20, 120, 2200) which at least partially surrounds the conductor,
A fire protection closure for preventing fire and smoke from penetrating from one room into another in case of fire, wherein the fire protection closure can be inserted into a wall opening having a reveal and a lintel, the wall opening connecting the two rooms and the fire protection closure comprising a glass door with at least one profile-free door leaf made of at least one fire protection pane, which door leaf is held in a pivoting manner into at least one direction, wherein at least one longitudinal side of the door leaf can be adjacent without any frame to the reveal of the wall opening, wherein the fire protection pane comprises two fireproof glass panes (7a, 7b) which are spaced apart in parallel from each other by means of an edging compound that forms an abutting edge, wherein the space enclosed by the edging compound between the fireproof glass panes (7a, 7b) is filled with a fire protection gel and the edging compound of the fire protection pane is offset inwards on at least one abutting edge while forming an abutting edge groove, wherein an intumescent strip is inserted into the abutting edge groove, characterized in that at least one sealing groove is formed in the intumescent strip, a seal being inserted into the sealing groove.
A thermoelectric conditioning arrangement (100; 200; 300), comprising: a first antenna or splitter (102; 202; 302) configured to transmit a power and control signal; a second antenna or splitter (104; 204; 304) configured to receive the power and control signal; a power converter (121; 221; 321) configured to receive the power and control signal from the second antenna or splitter (104; 204; 304) and generate a direct current, DC, signal; and a thermoelectric cooler, TEC, (130; 230; 330) configured to receive the DC signal from the power converter (121; 221; 321), characterised in that the thermoelectric conditioning arrangement (100; 200; 300) comprises a waveguide (110; 210; 310) coupled between the first antenna or splitter (102; 202; 302) and the second antenna or splitter (104; 204; 304), wherein the power and control signal is guided from the first antenna or splitter (102; 202; 302) to the second antenna or splitter (104; 204; 304) via the waveguide (110; 210; 310). a first antenna or splitter (102; 202; 302) configured to transmit a power and control signal; a second antenna or splitter (104; 204; 304) configured to receive the power and control signal; a power converter (121; 221; 321) configured to receive the power and control signal from the second antenna or splitter (104; 204; 304) and generate a direct current, DC, signal; and a thermoelectric cooler, TEC, (130; 230; 330) configured to receive the DC signal from the power converter (121; 221; 321), characterised in that the thermoelectric conditioning arrangement (100; 200; 300) comprises a waveguide (110; 210; 310) coupled between the first antenna or splitter (102; 202; 302) and the second antenna or splitter (104; 204; 304), wherein the power and control signal is guided from the first antenna or splitter (102; 202; 302) to the second antenna or splitter (104; 204; 304) via the waveguide (110; 210; 310).
A human T cell comprising a nucleic acid sequence encoding a chimeric antigen receptor, wherein the CAR comprises a CD19 antigen binding domain comprising the amino acid sequence of SEQ ID NO:37, wherein the antigen binding fragment is a scFv and the CAR further comprises a transmembrane domain, and an intracellular domain and a signaling domain of a costimulatory molecule.
A method of controlling the thermal charging of a PCM thermo-syphon evaporator in an air conditioning system, said method comprising the steps of: measuring the evaporator out air temperature and generating a State of Charge Indicator control signal as a function thereof; determining if said A/C system is operating in a transient cool-down mode or a steady state mode and generating an A/C operating mode signal as a function thereof; determining a PCM thermo-syphon evaporator charging priority; selecting a first predetermined blower voltage that is lower than standard air conditioning transient comfort control blower voltage when said PCM thermo-syphon evaporator charging priority is higher than the comfort maintenance priority to achieve PCM charging, and; selecting a second predetermined blower voltage as a function of said Change of State Signal that is lower than standard air conditioning comfort maintenance steady state blower voltage when said A/C system is operating in said steady-state mode and a blower voltage override is determined to be necessary. measuring the evaporator out air temperature and generating a State of Charge Indicator control signal as a function thereof; determining if said A/C system is operating in a transient cool-down mode or a steady state mode and generating an A/C operating mode signal as a function thereof; determining a PCM thermo-syphon evaporator charging priority; selecting a first predetermined blower voltage that is lower than standard air conditioning transient comfort control blower voltage when said PCM thermo-syphon evaporator charging priority is higher than the comfort maintenance priority to achieve PCM charging, and; selecting a second predetermined blower voltage as a function of said Change of State Signal that is lower than standard air conditioning comfort maintenance steady state blower voltage when said A/C system is operating in said steady-state mode and a blower voltage override is determined to be necessary.
A process for reducing or eliminating residual solvent in a crude organic compound containing at least one residual solvent comprising dissolving said compound in carbonated water to form a solution and freeze drying said solution.
An oral care composition comprising: a. a basic amino acid in free or salt form wherein the amino acid is arginine and wherein the arginine is present in an amount corresponding to 1% to 15%, the weight of the basic amino acid being calculated as free form; b. zinc oxide and zinc citrate, wherein the ratio of the amount of zinc oxide (by wt%) to zinc citrate (by wt%) is 2:1, and wherein the zinc citrate is in an amount of from 0.25 to 1.0 wt%, and zinc oxide is present in an amount of from 0.75 to 1.25 wt%, based on the weight of the oral care composition; c. a fluoride source d. glycerin, wherein the glycerin is in an amount of from 25% - 40%, based on the weight of the oral care composition. a. a basic amino acid in free or salt form wherein the amino acid is arginine and wherein the arginine is present in an amount corresponding to 1% to 15%, the weight of the basic amino acid being calculated as free form; b. zinc oxide and zinc citrate, wherein the ratio of the amount of zinc oxide (by wt%) to zinc citrate (by wt%) is 2:1, and wherein the zinc citrate is in an amount of from 0.25 to 1.0 wt%, and zinc oxide is present in an amount of from 0.75 to 1.25 wt%, based on the weight of the oral care composition; c. a fluoride source d. glycerin, wherein the glycerin is in an amount of from 25% - 40%, based on the weight of the oral care composition.